EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Exploring PIPAC for managing platinum resistant and refractory ovarian cancer with peritoneal spread: A collaborative multi-institutional study

Marco Tesei, Elisa Scarpelli, Maria Teresa Giudice, Barbara Costantini, Enrico Fiuzzi, Camelia Alexandra Coada, Vanda Salutari, Francesco Mezzapesa, Anna Fagotti, Pierandrea De Iaco, Giuseppe Vizzielli, Anna Myriam Perrone

European Journal of Surgical Oncology · 2026

DOI: 10.1016/j.ejso.2025.111161 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Surgical Oncology, 2026. Verfasst von Marco Tesei und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncologic Gynecology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Peritoneal Neoplasms, Carcinoma, Ovarian Epithelial, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Platinum-resistant or refractory epithelial ovarian cancer (EOC) remains a significant clinical challenge, often leading to rapid progression and poor prognosis. Palliative treatments aimed at improving quality of life are warranted. OBJECTIVE: To assess the feasibility and potential benefits of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in patients with platinum-resistant or refractory EOC. METHODS: Prospective multicenter observational study (2016-2023). PRIMARY ENDPOINT: feasibility, defined as completion of ≥3 planned PIPAC cycles within 120 days without ≥ grade 3 treatment related adverse events (CTCAE v5.0). Secondary endpoints: safety; disease control (RECIST 1.1); changes in Peritoneal Cancer Index and Fagotti score; ascites control; CA-125 response; conversion to cytoreductive surgery (±HIPEC); and overall survival (OS). RESULTS: Forty patients were enrolled. Ninety-seven percent of procedures were completed. Feasibility was 65.0 % (26/40; 95 % CI 49.51-77.87); no grade ≥3 events occurred. Key secondary outcomes included a clinical benefit rate of 35 % in the intention-to-treat (ITT) population and 53.8 % in the per-protocol (PP) population, median time to ascites resolution of one cycle, and median overall survival of 14 months (17 months in PP). Higher white blood cell count and ascites volume were significantly associated with progression (p = 0.035 and p = 0.025). Three platinum-refractory patients became eligible for surgery, two underwent optimal cytoreduction. Median OS was 14 months (17 months in PP). A non-significant trend toward longer OS was observed in platinum-refractory versus platinum-resistant disease (18 vs 9 months; p = 0.093). CONCLUSIONS: PIPAC is a feasible, well-tolerated option in platinum-resistant and refractory EOC with potential to stabilize disease, relieve ascites and enable surgery in selected cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsPeritoneal NeoplasmsCarcinoma, Ovarian EpithelialAntineoplastic AgentsHumansFemaleMiddle AgedDrug Resistance, NeoplasmProspective StudiesAgedFeasibility StudiesAdultCytoreduction Surgical ProceduresSurvival RatePaclitaxel

Stichwörter der Autor:innen

CarcinomatosisChemoresistanceOvarian cancerPIPACPalliative therapy

Substanzen

Antineoplastic AgentsPaclitaxel

Autor:innen und Institutionen

  • Division of Oncologic Gynecology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Division of Oncologic Gynecology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
  • Department of Women, Children and Public Health Sciences, Gynecologic Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Department of Women, Children and Public Health Sciences, Gynecologic Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; Saint Camillus International, University of Health Sciences,…
  • Division of Physiology, Department of Morpho-functional Sciences, University of Medicine and Pharmacy 'Iuliu Hațieganu', Cluj-Napoca, Romania.
  • Division of Oncologic Gynecology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. Electronic address: franc…

Zitieren

APA

Tesei, M., Scarpelli, E., Giudice, M. T., Costantini, B., Fiuzzi, E., Coada, C. A., Salutari, V., Mezzapesa, F., Fagotti, A., De Iaco, P., Vizzielli, G., & Perrone, A. M. (2026). Exploring PIPAC for managing platinum resistant and refractory ovarian cancer with peritoneal spread: A collaborative multi-institutional study. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2025.111161

Vancouver

Tesei M, Scarpelli E, Giudice MT, Costantini B, Fiuzzi E, Coada CA, et al. Exploring PIPAC for managing platinum resistant and refractory ovarian cancer with peritoneal spread: A collaborative multi-institutional study. European Journal of Surgical Oncology. 2026. doi:10.1016/j.ejso.2025.111161

BibTeX
@article{Tesei2026,
  author = {Tesei, Marco and Scarpelli, Elisa and Giudice, Maria Teresa and Costantini, Barbara and Fiuzzi, Enrico and Coada, Camelia Alexandra and Salutari, Vanda and Mezzapesa, Francesco and Fagotti, Anna and De Iaco, Pierandrea and Vizzielli, Giuseppe and Perrone, Anna Myriam},
  title = {Exploring PIPAC for managing platinum resistant and refractory ovarian cancer with peritoneal spread: A collaborative multi-institutional study},
  journal = {European Journal of Surgical Oncology},
  year = {2026},
  doi = {10.1016/j.ejso.2025.111161}
}
Kostenlos starten →